Form 4: REVB Director Jess Roper Acquires Future Stock Grant

Revelation Biosciences Director Jess Roper reported the future acquisition of 15,625 shares of common stock at $1.28 per share through a restricted stock grant.

Summary

• Jess Roper, a Director of Revelation Biosciences, Inc. (REVB), reported the acquisition of 15,625 shares of common stock.
• The transaction date for this acquisition is October 29, 2025.
• The shares were acquired at a price of $1.28 per share.
• This acquisition is a Restricted Stock Grant under the company's 2021 Equity Incentive Plan.
• The granted shares will vest 100% on January 28, 2026.
• Following this reported transaction, Jess Roper will beneficially own 15,686 shares of common stock directly.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even as a restricted stock grant, is generally a positive signal of alignment with shareholder interests, though it's a pre-planned compensation event rather than an open-market purchase.

Positives

• The acquisition of shares by a director, even as a grant, aligns management's interests with those of shareholders, potentially signaling confidence in the company's future.
• The grant is part of an existing 2021 Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Future Outlook

The restricted stock grant is scheduled to vest 100% on January 28, 2026, indicating a future increase in the director's fully vested beneficial ownership.

Industry Context

This filing represents a routine insider transaction report, common across publicly traded companies, detailing changes in beneficial ownership for directors or officers, often related to compensation plans.

Corporate Governance

Related Party Transactions

• The acquisition of 15,625 shares of common stock by Director Jess Roper through a restricted stock grant from Revelation Biosciences, Inc. constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the director's increased beneficial ownership as a positive indicator of management's commitment and belief in the company's future prospects.

Next Steps

• The restricted stock grant will vest 100% on January 28, 2026.

Key Dates

Recommendation

While the director's acquisition of shares, even through a grant, is a positive signal of alignment and confidence, this Form 4 filing alone does not provide sufficient financial or operational details to warrant a stronger recommendation. It's a routine compensation event that reinforces insider interest but doesn't present new fundamental catalysts for immediate investment action.

Keywords

REVELATION BIOSCIENCES, REVB, Jess Roper, Form 4, Insider Transaction, Stock Grant, Director, Equity Incentive Plan, Beneficial Ownership